Rho kinases in health and disease: From basic science to translational research

Pharmacological Reviews

Volumn 67, Issue 4, 2015, Pages 1074-1095

  Loirand, Gervaise ^a  

^a L INSTITUT DU THORAX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FASUDIL; GSK 269962A; H 1152; MYOSIN LIGHT CHAIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; RHO KINASE 1; RHO KINASE 2; RHO KINASE INHIBITOR; SB 772077B; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GLUCOSE; ROCK1 PROTEIN, HUMAN; ROCK2 PROTEIN, HUMAN;

ACTIN FILAMENT; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANGINA PECTORIS; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD PRESSURE; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; DISEASE PREDISPOSITION; ENZYME ACTIVITY; GLAUCOMA; HUMAN; HYPERTENSION; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SPASTICITY; SPINAL CORD INJURY; SUBARACHNOID HEMORRHAGE; ANIMAL; CARDIOVASCULAR DISEASE; CELL MOTION; ENDOTHELIUM; GENETICS; INFLAMMATION; KIDNEY DISEASE; LEUKOCYTE; METABOLISM; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE; TRANSGENIC ANIMAL;

ACTIN CYTOSKELETON; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ASTHMA; AUTOIMMUNE DISEASES; BIOMARKERS; CARDIOVASCULAR DISEASES; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIUM; GLAUCOMA; GLUCOSE; HUMANS; INFLAMMATION; KIDNEY DISEASES; LEUKOCYTES; MUSCLE, SMOOTH; NEOPLASMS; NERVOUS SYSTEM DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84942900076     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.115.010595     Document Type: Review

References (211)

1. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, and Sueishi K, et al. (2004) Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hyper¬tension in rats. Circ Res 94:385-393.
2. Akagi EM, Lavorato-Rocha AM, Maia BdeM, Rodrigues IS, Carvalho KC, Stiepcich MM, Baiocchi G, Sato-Kuwabara Y, Rogatto SR, and Soares FA, et al. (2014) ROCK1 as a novel prognostic marker in vulvar cancer. BMC Cancer 14:822.
3. Amano M, Chihara K, Nakamura N, Kaneko T, Matsuura Y, and Kaibuchi K (1999) The COOH terminus of Rho-kinase negatively regulates rho-kinase activity. J Biol Chem 274:32418-32424.
4. Amano M, Fukata Y, Shimokawa H, and Kaibuchi K (2000) Purification and in vitro activity of Rho-associated kinase. Methods Enzymol 325:149-155.
5. Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S, Zandi S, Almulki L, Tayyari F, and Shimokawa H, et al. (2009) Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 58:215-226.
6. Bacharach J, Dubiner HB, Levy B, Kopczynski CC, and Novack GD; AR-13324-CS202 Study Group (2015) Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology 122:302-307.
7. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, and Cohen P (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297-315.
8. Bhandary L, Whipple RA, Vitolo MI, Charpentier MS, Boggs AE, Chakrabarti KR, Thompson KN, and Martin SS (2015) ROCK inhibition promotes microtentacles that enhance reattachment of breast cancer cells. Oncotarget 6:6251-6266.
9. Biswas PS, Gupta S, Chang E, Song L, Stirzaker RA, Liao JK, Bhagat G, and Pernis AB (2010) Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 pro¬duction and the development of autoimmunity in mice. J Clin Invest 120: 3280-3295.
10. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, Lewis RL, Mills TM, Hellstrom WJ, and Kadowitz PJ (2004) RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 101:9121-9126.
11. Boerma M, Fu Q, Wang J, Loose DS, Bartolozzi A, Ellis JL, McGonigle S, Paradise E, Sweetnam P, and Fink LM, et al. (2008) Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor ofRho kinase or atorvastatin. Blood Coagul Fibrinolysis 19:709-718.
12. Bottino J, Gelaleti GB, Maschio LB, Jardim-Perassi BV, and de Campos Zuccari DAP (2014) Immunoexpression of ROCK-1 and MMP-9 as prognostic markers in breast cancer. Acta Histochem 116:1367-1373.
13. Brown JH, Del Re DP, and Sussman MA (2006) The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 98:730-742.
14. Chang J, Xie M, Shah VR, Schneider MD, Entman ML, Wei L, and Schwartz RJ (2006) Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc Natl Acad Sci USA 103:14495-14500.
15. Chen CP, Chen X, Qiao YN, Wang P, He WQ, Zhang CH, Zhao W, Gao YQ, Chen C, and Tao T, et al. (2015) In vivo roles for myosin phosphatase targeting subunit-1 phosphorylation sites T694 and T852 in bladder smooth muscle contraction. J Physiol 593:681-700.
16. Chen XQ, Tan I, Ng CH, Hall C, Lim L, and Leung T (2002) Characterization of RhoA-binding kinase ROKalpha implication of the pleckstrin homology domain in ROKalpha function using region-specific antibodies. J Biol Chem 277: 12680-12688.
17. Cheng CI, Lin YC, Tsai TH, Lin HS, Liou CW, Chang WN, Lu CH, Yuen CM, and Yip HK (2014) The prognostic values ofleukocyte Rho kinase activity in acute ischemic stroke. BioMed Res Int 2014:214587.
18. Chevrier V, Piel M, Collomb N, Saoudi Y, Frank R, Paintrand M, Narumiya S, Bornens M, and Job D (2002) The Rho-associated protein kinase p160ROCK is required for centrosome positioning. J Cell Biol 157:807-817.
19. Chuang HH, Yang CH, Tsay YG, Hsu CY, Tseng LM, Chang ZF, and Lee HH (2012) ROCKII Ser1366 phosphorylation reflects the activation status. Biochem J 443: 145-151.
20. Cicek FA, Kandilci HB, and Turan B (2013) Role of ROCK upregulation in endo¬thelial and smooth muscle vascular functions in diabetic rat aorta. Cardiovasc Diabetol 12:51.
21. Couch BA, DeMarco GJ, Gourley SL, and Koleske AJ (2010) Increased dendrite branching in AbetaPP/PS1 mice and elongation of dendrite arbors by fasudil ad¬ministration. J Alzheimers Dis 20:1003-1008.
22. Creager MA, Lüscher TF, Cosentino F, and Beckman JA (2003) Diabetes and vas¬cular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108:1527-1532.
23. Davis GE, Stratman AN, Sacharidou A, and Koh W (2011) Molecular basis for en¬dothelial lumen formation and tubulogenesis during vasculogenesis and angiogenic sprouting. Int Rev Cell Mol Biol 288:101-165.
24. Demiryürek S, Okumus S, Bozgeyik Í, Oztuzcu S, Coskun E, Mat E, Durucu E, Tatar MG, Erbagci Í, and Gürler B, et al. (2015) investigation of the Rho-kinase gene polymorphism in primary open-angle glaucoma. Ophthalmic Genet DOi: 10. 3109/ 13816810.2014.895016 [published ahead of print].
25. Dergham P, Ellezam B, Essagian C, Avedissian H, Lubell WD, and McKerracher L (2002) Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 22:6570-6577.
26. Doe Z, Fukumoto Y, Sugimura K, Miura Y, Tatebe S, Yamamoto S, Aoki T, Nochioka K, Nergui S, and Yaoita N, et al. (2013) Rho-kinase activation in patients with heart failure. Circ J 77:2542-2550.
27. Doe Z, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, Tada T, Saji K, Sugimura K, and Fujita H, et al. (2009) Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 73:1731-1739.
28. Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, and Wright LL, et al. (2007) Novel Rho kinase inhibitors with anti¬inflammatory and vasodilatory activities. J Pharmacol Exp Ther 320:89-98.
29. Dong M, Jiang X, Liao JK, and Yan BP (2013) Elevated rho-kinase activity as a marker indicating atherosclerosis and inflammation burden in polyvascular disease patients with concomitant coronary and peripheral arterial disease. Clin Cardiol 36:347-351.
30. Dong M, Liao JK, Fang F, Lee APW, Yan BPY, Liu M, and Yu CM (2012) Íncreased Rho kinase activity in congestive heart failure. Eur J Heart Fail 14:965-973.
31. Doran JD, Liu X, Taslimi P, Saadat A, and Fox T (2004) New insights into the structure-function relationships of Rho-associated kinase: a thermodynamic and hydrodynamic study of the dimer-to-monomer transition and its kinetic implica¬tions. Biochem J 384:255-262.
32. Fagan KA, Oka M, Bauer NR, Gebb SA, Ívy DD, Morris KG, and McMurtry ÍF (2004) Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 287:L656-L664.
33. Farah S, Agazie Y, Ohan N, Ngsee JK, and Liu XJ (1998) A rho-associated protein kinase, ROKalpha, binds insulin receptor substrate-1 and modulates insulin sig¬naling. J Biol Chem 273:4740-4746.
34. Fava A, Wung PK, Wigley FM, Hummers LK, Daya NR, Ghazarian SR, and Boin F (2012) Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud’s phenome¬non. Arthritis Care Res (Hoboken) 64:925-929.
35. Fehlings MG, Theodore N, Harrop J, Maurais G, Kuntz C, Shaffrey CÍ, Kwon BK, Chapman J, Yee A, and Tighe A, et al. (2011) A phase Í/ÍÍa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma 28:787-796.
36. Feng J, Íto M, Kureishi Y, Íchikawa K, Amano M, Ísaka N, Okawa K, Íwamatsu A, Kaibuchi K, and Hartshorne DJ, et al. (1999) Rho-associated kinase of chicken gizzard smooth muscle. J Biol Chem 274:3744-3752.
37. Feng Y and LoGrasso PV (2014) Rho kinase inhibitors: a patent review (2012-2013). Expert Opin Ther Pat 24:295-307.
38. Feske SK, Sorond FA, Henderson GV, Seto M, Hitomi A, Kawasaki K, Sasaki Y, Asano T, and Liao JK (2009) increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res 1257:89-93.
39. Fournier AE, Takizawa BT, and Strittmatter SM (2003) Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci 23:1416-1423.
40. Fu P, Liu F, Su S, Wang W, Huang XR, Entman ML, Schwartz RJ, Wei L, and Lan HY (2006) Signaling mechanism ofrenal fibrosis in unilateral ureteral obstructive kidney disease in ROCK1 knockout mice. J Am Soc Nephrol 17:3105-3114.
41. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, and Shimokawa H (2010) Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25:144-149.
42. Fujita Y and Yamashita T (2014) Axon growth inhibition by RhoA/ROCK in the central nervous system. Front Neurosci 8:338.
43. Fukumoto Y, Matoba T, ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, and Shimokawa H (2005) Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91:391-392.
44. Fukumoto Y, Yamada N, Matsubara H, Mizoguchi M, Uchino K, Yao A, Kihara Y, Kawano M, Watanabe H, and Takeda Y, et al. (2013) Double-blind, placebo¬controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hyper¬tension. Circ J 77:2619-2625.
45. Furukawa N, Ongusaha P, Jahng WJ, Araki K, Choi CS, Kim HJ, Lee YH, Kaibuchi K, Kahn BB, and Masuzaki H, et al. (2005) Role of Rho-kinase in regulation of insulin action and glucose homeostasis. Cell Metab 2:119-129.
46. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, and Stevens C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153-158.
47. Guan R, Xu X, Chen M, Hu H, Ge H, Wen S, Zhou S, and Pi R (2013) Advances in the studies ofroles ofRho/Rho-kinase in diseases and the development ofits inhibitors. Eur J Med Chem 70:613-622.
48. Guérin P, Sauzeau V, Rolli-Derkinderen M, Al Habbash O, Scalbert E, Crochet D, Pacaud P, and Loirand G (2005) Stent implantation activates RhoA in human arteries: inhibitory effect of rapamycin. J Vasc Res 42:21-28.
49. Gutjahr MC, Rossy J, and Niggli V (2005) Role of Rho, Rac, and Rho-kinase in phosphorylation of myosin light chain, development of polarity, and sponta¬neous migration of Walker 256 carcinosarcoma cells. Exp Cell Res 308: 422-438.
50. Hara M, Takayasu M, Watanabe K, Noda A, Takagi T, Suzuki Y, and Yoshida J (2000) Protein kinase inhibition by fasudil hydrochloride promotes neurological recovery after spinal cord injury in rats. J Neurosurg 93(1, Suppl)94-101.
51. Hata T, Goto C, Soga J, Hidaka T, Fujii Y, idei N, Fujimura N, Maruhashi T, Mikami S, and Kihara Y, et al. (2011a) Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vas¬cular response to fasudil. Atherosclerosis 214:117-121.
52. Hata T, Soga J, Hidaka T, idei N, Fujii Y, Fujimura N, Mikami S, Maruhashi T, Kihara Y, and Chayama K, et al.; ROCK Study Group (2011b) Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. J Hypertens 29:373-379.
53. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Tsutsui H, Kaibuchi K, and Takeshita A (2004) Long-term inhibition of Rho-kinase suppresses left ven¬tricular remodeling after myocardial infarction in mice. Circulation 109: 2234-2239.
54. Hayashi K, Wakino S, Kanda T, Homma K, Sugano N, and Saruta T (2006) Molecular mechanisms and therapeutic strategies ofchronic renal injury: role ofrho-kinase in the development of renal injury. J Pharmacol Sci 100:29-33.
55. He Y, Xu H, Liang L, Zhan Z, Yang X, Yu X, Ye Y, and Sun L (2008) Antiin¬flammatory effect ofRho kinase blockade via inhibition ofNF-kappaB activation in rheumatoid arthritis. Arthritis Rheum 58:3366-3376.
56. Heemskerk N, van Rijssel J, and van Buul JD (2014) Rho-GTPase signaling in leu¬kocyte extravasation: an endothelial point of view. Cell Adhes Migr 8:67-75.
57. Herskowitz JH, Feng Y, Mattheyses AL, Hales CM, Higginbotham LA, Duong DM, Montine TJ, Troncoso JC, Thambisetty M, and Seyfried NT, et al. (2013) Phar¬macologic inhibition of ROCK2 suppresses amyloid-ß production in an Alzheimer’s disease mouse model. J Neurosci 33:19086-19098.
58. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, ichiki T, Takahashi S, and Takeshita A (2003) Long-term inhibition of Rho-kinase sup¬presses angiotensin ii-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 93:767-775.
59. Horowitz S, Binion DG, Nelson VM, Kanaa Y, Javadi P, Lazarova Z, Andrekopoulos C, Kalyanaraman B, Otterson MF, and Rafiee P (2007) increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 292:G1323-G1336.
60. Hoshijima M, Sah VP, Wang Y, Chien KR, and Brown JH (1998) The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. involvement of Rho kinase. J Biol Chem 273:7725-7730.
61. Hou Y, Zhou L, Yang QD, Du XP, Li M, Yuan M, and Zhou ZW (2012) Changes in hippocampal synapses and learning-memory abilities in a streptozotocin-treated rat model and intervention by using fasudil hydrochloride. Neuroscience 200: 120-129.
62. Hung MJ, Cherng WJ, Hung MY, Kuo LT, Cheng CW, Wang CH, Yang Ni, and Liao JK (2012) increased leukocyte Rho-associated coiled-coil containing protein kinase activity predicts the presence and severity of coronary vasospastic angina. Ath¬erosclerosis 221:521-526.
63. Inoue T and Tanihara H (2013) Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res 37:1-12.
64. Isgro J, Gupta S, Jacek E, Pavri T, Duculan R, Kim M, Kirou KA, Salmon JE, and Pernis AB (2013) Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus. Arthritis Rheum 65:1592-1602.
65. Ishikawa Y, Nishikimi T, Akimoto K, ishimura K, Ono H, and Matsuoka H (2006) Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 47:1075-1083.
66. Ishikura K, Yamada N, ito M, Ota S, Nakamura M, isaka N, and Nakano T (2006) Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 70:174-178.
67. Isobe T, Mizuno K, Kaneko Y, Ohta M, Koide T, and Tanabe S (2014) Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res 39:813-822.
68. Kahles T, Luedike P, Endres M, Galla H-J, Steinmetz H, Busse R, Neumann-Haefelin T, and Brandes RP (2007) NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 38:3000-3006.
69. Kajikawa M, Noma K, Maruhashi T, Mikami S, iwamoto Y, iwamoto A, Matsumoto T, Hidaka T, Kihara Y, and Chayama K, et al. (2014) Rho-associated kinase ac¬tivity is a predictor of cardiovascular outcomes. Hypertension 63:856-864.
70. Kalender ME, Demiryürek S, Oztuzcu S, Kizilyer A, Demiryürek AT, Sevinc A, Dikilitas M, Yildiz R, and Camci C (2010) Association between the Thr431Asn polymorphism of the ROCK2 gene and risk of developing metastases of breast cancer. Oncol Res 18:583-591.
71. Kamai T, Tsujii T, Arai K, Takagi K, Asami H, ito Y, and Oshima H (2003) Signif¬icant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9:2632-2641.
72. Kamijo H, Matsumura Y, Thumkeo D, Koike S, Masu M, Shimizu Y, ishizaki T, and Narumiya S (2011) impaired vascular remodeling in the yolk sac of embryos deficient in ROCK-i and ROCK-ii. Genes Cells 16:1012-1021.
73. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, and Saruta T (2003) Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontane¬ously hypertensive rats. Kidney Int 64:2009-2019.
74. Kanda T, Wakino S, Homma K, Yoshioka K, Tatematsu S, Hasegawa K, Takamatsui, Sugano N, Hayashi K, and Saruta T (2006) Rho-kinase as a molecular target for insulin resistance and hypertension. FASEB J 20:169-171.
75. Kasahara Di, Ninin FM, Wurmbrand AP, Liao JK, and Shore SA (2015) Abrogation of airway hyperresponsiveness but not inflammation by rho kinase insufficiency. Clin Exp Allergy 45:457-470.
76. Kikuchi Y, Yamada M, imakiire T, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Oda T, Suzuki S, and Miura S (2007) A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 192:595-603.
77. Kikuchi Y, Yasuda S, Aizawa K, Tsuburaya R, ito Y, Takeda M, Nakayama M, ito K, Takahashi J, and Shimokawa H (2011) Enhanced Rho-kinase activity in circulating neutrophils of patients with vasospastic angina: a possible bio¬marker for diagnosis and disease activity assessment. J Am Coll Cardiol 58: 1231-1237.
78. Knipe RS, Tager AM, and Liao JK (2015) The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev 67:103-117.
79. Kobayashi N, Horinaka S, Mita S, Nakano S, Honda T, Yoshida K, Kobayashi T, and Matsuoka H (2002) Critical role of Rho-kinase pathway for cardiac perfor¬mance and remodeling in failing rat hearts. Cardiovasc Res 55:757-767.
80. Kolavennu V, Zeng L, Peng H, Wang Y, and Danesh FR (2008) Targeting of RhoA/ ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 57:714-723.
81. Kuwahara K, Kinoshita H, Kuwabara Y, Nakagawa Y, Usami S, Minami T, Yamada Y, Fujiwara M, and Nakao K (2010) Myocardin-related transcription factor A is a common mediator of mechanical stress-and neurohumoral stimulation-induced cardiac hypertrophic signaling leading to activation of brain natriuretic peptide gene expression. Mol Cell Biol 30:4134-4148.
82. Lane J, Martin TA, Watkins G, Mansel RE, and Jiang WG (2008) The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int JOncol 33:585-593.
83. Laufs U and Liao JK (1998) Post-transcriptional regulation ofendothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273:24266-24271.
84. Lee DH, Shi J, Jeoung NH, Kim MS, Zabolotny JM, Lee SW, White MF, Wei L, and Kim YB (2009) Targeted disruption of ROCK1 causes insulin resistance in vivo. J Biol Chem 284:11776-11780.
85. Lee HH, Tien SC, Jou TS, Chang YC, Jhong JG, and Chang ZF (2010) Src-dependent phosphorylation of ROCK participates in regulation of focal adhesion dynamics. J Cell Sci 123:3368-3377.
86. Lee JH, Zheng Y, von Bornstadt D, Wei Y, Balcioglu A, Daneshmand A, Yalcin N, Yu E, Herisson F, and Atalay YB, et al. (2014a) Selective ROCK2 inhibition in focal cerebral ischemia. Ann Clin Transl Neurol 1:2-14.
87. Lee SH, Huang H, Choi K, Lee DH, Shi J, Liu T, Chun KH, Seo JA, Lima IS, and Zabolotny JM, et al. (2014b) ROCK1 isoform-specific deletion reveals a role for diet-induced insulin resistance. Am J Physiol Endocrinol Metab 306:E332-E343.
88. Leung T, Chen XQ, Manser E, and Lim L (1996) The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol CellBiol 16:5313-5327.
89. Leung T, Manser E, Tan L, and Lim L (1995) A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral mem¬branes. JBiol Chem 270:29051-29054.
90. Li M, Huang Y, Ma AA, Lin E, and Diamond MI (2009) Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol Dis 36: 413-420.
91. Li Q, Xu Y, Li X, Guo Y, and Liu G (2012a) Inhibition of Rho-kinase ameliorates myocardial remodeling and fibrosis in pressure overload and myocardial infarction: role of TGF-ß1-TAK1. ToxicolLett 211:91-97.
92. Li R, Martin MP, Liu Y, Wang B, Patel RA, Zhu JY, Sun N, Pireddu R, Lawrence NJ, and Li J, et al. (2012b) Fragment-based and structure-guided discovery and opti¬mization of Rho kinase inhibitors. J Med Chem 55:2474-2478.
93. Li Y, Harada T, Juang YT, Kyttaris VC, Wang Y, Zidanic M, Tung K, and Tsokos GC (2007) Phosphorylated ERM is responsible for increased T cell polarization, ad¬hesion, and migration in patients with systemic lupus erythematosus. J Immunol 178:1938-1947.
94. Liao YC, Liu PY, Lin HF, Lin WY, Liao JK, and Juo SH (2015) Two functional polymorphisms of ROCK2 enhance arterial stiffening through inhibiting its ac¬tivity and expression. J Mol Cell Cardiol 79:180-186.
95. Liu GJ, Wang Zj, Wang YF, Xu LL, Wang XL, Liu Y, Luo GJ, He GH, and Zeng YJ (2012) Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. Eur J Clin Pharmacol 68:131-139.
96. Liu L, Cao Y, Cui G, Li Z, Sun J, Zhang L, Chen C, Wang Y, Wang P, and Ding H, et al. (2013) Association analysis of polymorphisms in ROCK2 with cardiovascular disease in a Chinese population. PLoS One 8:e53905.
97. Liu PY, Chen JH, Lin LJ, and Liao JK (2007) Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol 49:1619-1624.
98. Liu PY, Liu YW, Lin LJ, Chen JH, and Liao JK (2009a) Evidence for statin pleiotropy in humans: differential effects ofstatins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circu¬lation 119:131-138.
99. Liu S, Goldstein RH, Scepansky EM, and Rosenblatt M (2009b) Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. CancerRes 69:8742-8751.
100. Liu X, Choy E, Hornicek FJ, Yang S, Yang C, Harmon D, Mankin H, and Duan Z (2011) ROCK1 as a potential therapeutic target in osteosarcoma. J Orthop Res 29: 1259-1266.
101. Lochhead PA, Wickman G, Mezna M, and Olson MF (2010) Activating ROCK1 so¬matic mutations in human cancer. Oncogene 29:2591-2598.
102. Löhn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, Schaefer M, Linz W, Kohlmann M, and Herbert JM, et al. (2009) Pharmacological charac¬terization of SAR407899, a novel rho-kinase inhibitor. Hypertension 54:676-683.
103. Loirand G, Guérin P, and Pacaud P (2006) Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98:322-334.
104. Loirand G and Pacaud P (2010) The role of Rho protein signaling in hypertension. Nat Rev Cardiol 7:637-647.
105. Loirand G, Sauzeau V, and Pacaud P (2013) Small G proteins in the cardiovascular system: physiological and pathological aspects. Physiol Rev 93:1659-1720.
106. Lowery DM, Clauser KR, Hjerrild M, Lim D, Alexander J, Kishi K, Ong SE, Gammeltoft S, Carr SA, and Yaffe MB (2007) Proteomic screen defines the Polo¬box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J 26: 2262-2273.
107. Mallat Z, Gojova A, Sauzeau V, Brun V, Silvestre JS, Esposito B, Merval R, Groux H, Loirand G, and Tedgui A (2003) Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res 93: 884-888.
108. Manser E, Leung T, Salihuddin H, Zhao ZS, and Lim L (1994) A brain serine/ threonine protein kinase activated by Cdc42 and Rac1. Nature 367:40-6.
109. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, and Takeshita A (2001) Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 38:1307-1310.
110. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, and Takeshita A (2002) Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105:1545-1547.
111. Matsumoto Y, Uwatoku T, Oi K, Abe K, Hattori T, Morishige K, Eto Y, Fukumoto Y, Nakamura K, and Shibata Y, et al. (2004) Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol 24: 181-186.
112. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L, Hayoz D, Ruffieux J, Rusconi S, and Montani JP, et al. (2004) Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 110: 3708-3714.
113. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, and Yang Z (2002) Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 22:8467-8477.
114. Mita S, Kobayashi N, Yoshida K, Nakano S, and Matsuoka H (2005) Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats. J Hypertens 23:87-96.
115. Morgan-Fisher M, Wewer UM, and Yoneda A (2013) Regulation of ROCK activity in cancer. J Histochem Cytochem 61:185-198.
116. Mueller BK, Mack H, and Teusch N (2005) Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 4:387-398.
117. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, McMurtry IF, and Oka M (2005) Inhaled Rho kinase inhibitors are potent and selective vaso¬dilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171:494-499.
118. Nagaoka T, Morio Y, Casanova N, Bauer N, Gebb S, McMurtry I, and Oka M (2004) Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 287:L665-L672.
119. Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T, Ando A, Imai E, and Hori M (2002) Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 61:1684-1695.
120. Nishikimi T, Akimoto K, Wang X, Mori Y, Tadokoro K, Ishikawa Y, Shimokawa H, Ono H, and Matsuoka H (2004) Fasudil, a Rho-kinase inhibitor, attenuates glo¬merulosclerosis in Dahl salt-sensitive rats. J Hypertens 22:1787-1796.
121. Nishimura T and Takeichi M (2008) Shroom3-mediated recruitment of Rho kinases to the apical cell junctions regulates epithelial and neuroepithelial planar remodeling. Development 135:1493-1502.
122. Noma K, Rikitake Y, Oyama N, Yan G, Alcaide P, Liu PY, Wang H, Ahl D, Sawada N, and Okamoto R, et al. (2008) ROCK1 mediates leukocyte recruitment and neo¬intima formation following vascular injury. J Clin Invest 118:1632-1644.
123. Nuno DW and Lamping KG (2010) The role of rho kinase in sex-dependent vascular dysfunction in type 1 diabetes. Exp Diabetes Res 2010:176361.
124. Ocaranza MP, Gabrielli L, Mora I, Garcia L, McNab P, Godoy I, Braun S, Córdova S, Castro P, and Novoa U, et al. (2011) Markedly increased Rho-kinase activity in circulating leukocytes in patients with chronic heart failure. Am Heart J 161: 931-937.
125. Oguz E, Alasehirli B, Pehlivan Y, Onat AM, Oztuzcu S, Ozkara E, Kisacik B, Camci C, and Demiryürek AT (2012) Association between Rho-kinase (ROCK2) gene polymorphisms and Behçet’s disease. Transl Res 160:428-434.
126. Okamoto R, Li Y, Noma K, Hiroi Y, Liu PY, Taniguchi M, Ito M, and Liao JK (2013) FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB J 27:1439-1449.
127. Paintlia AS, Paintlia MK, Hollis BW, Singh AK, and Singh I (2012) Interference with RhoA-ROCK signaling mechanism in autoreactive CD4+ T cells enhances the bioavailability of 1, 25-dihydroxyvitamin D3 in experimental autoimmune en¬cephalomyelitis. Am J Pathol 181:993-1006.
128. Palomino Doza J, Topf A, Bentham J, Bhattacharya S, Cosgrove C, Brook JD, Granados-Riveron J, Bu’Lock FA, O’Sullivan J, and Stuart AG, et al. (2013) Low-frequency intermediate penetrance variants in the ROCK1 gene predispose to Tetralogy of Fallot. BMC Genet 14:57.
129. Pan P, Shen M, Yu H, Li Y, Li D, and Hou T (2013) Advances in the development of Rho-associated protein kinase (ROCK) inhibitors. Drug Discov Today 18: 1323-1333.
130. Patel RA, Liu Y, Wang B, Li R, and Sebti SM (2014) Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene 33:550-555.
131. Pinner S and Sahai E (2008) PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol 10:127-137.
132. Rankinen T, Church T, Rice T, Markward N, Blair SN, and Bouchard C (2008) A major haplotype block at the rho-associated kinase 2 locus is associated with a lower risk of hypertension in a recessive manner: the HYPGENE study. Hyper-tens Res 31:1651-1657.
133. Rath N and Olson MF (2012) Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep 13:900-908.
134. Ray P, Wright J, Adam J, Bennett J, Boucharens S, Black D, Cook A, Brown AR, Epemolu O, and Fletcher D, et al. (2011) Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors. Bioorg Med Chem Lett 21:97-101.
135. Reedquist KA and Tak PP (2012) Signal transduction pathways in chronic in¬flammatory autoimmune disease: small GTPases. Open Rheumatol J 6:259-272.
136. Riento K and Ridley AJ (2003) Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4:446-456.
137. Rikitake Y and Liao JK (2005) Rho GTPases, statins, and nitric oxide. Circ Res 97: 1232-1235.
138. Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH, and Liao JK (2005) Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/-hap-loinsufficient mice. Circulation 112:2959-2965.
139. Salminen A, Suuronen T, and Kaarniranta K (2008) ROCK, PAK, and Toll of syn¬apses in Alzheimer’s disease. Biochem Biophys Res Commun 371:587-590.
140. Sapet C, Simoncini S, Loriod B, Puthier D, Sampol J, Nguyen C, Dignat-George F, and Anfosso F (2006) Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood 108:1868-1876.
141. Sari I, Berberoglu B, Ozkara E, Oztuzcu S, Camci C, and Demiryurek AT (2013) Role of rho-kinase gene polymorphisms and protein expressions in colorectal cancer development. Pathobiology 80:138-145.
142. Sasaki Y, Suzuki M, and Hidaka H (2002) The novel and specific Rho-kinase in¬hibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 93: 225-232.
143. Satoh S, Ueda Y, Koyanagi M, Kadokami T, Sugano M, Yoshikawa Y, and Makino N (2003) Chronic inhibition of Rho kinase blunts the process of left ventricular hy¬pertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J Mol Cell Cardiol 35:59-70.
144. Satoh S, Utsunomiya T, Tsurui K, Kobayashi T, Ikegaki I, Sasaki Y, and Asano T (2001) Pharmacological profile ofhydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci 69:1441-1453.
145. Satoh S, Yamaguchi T, Hitomi A, Sato N, Shiraiwa K, Ikegaki I, Asano T, and Shimokawa H (2002) Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol 455:169-174.
146. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun TH, Inoue M, Masatsugu K, Saito T, and Fukunaga Y, et al. (2000) Inhibition of rho-associated kinase results in suppres¬sion of neointimal formation of balloon-injured arteries. Circulation 101:2030-2033.
147. Schaafsma D, Bos IS, Zuidhof AB, Zaagsma J, and Meurs H (2006) Inhalation of the Rho-kinase inhibitor Y-27632 reverses allergen-induced airway hyperrespon¬siveness after the early and late asthmatic reaction. Respir Res 7:121.
148. Schaafsma D, Bos IS, Zuidhof AB, Zaagsma J, and Meurs H (2008) The inhaled Rho kinase inhibitor Y-27632 protects against allergen-induced acute bronchocon-striction, airway hyperresponsiveness, and inflammation. Am J Physiol Lung Cell Mol Physiol 295:L214-L219.
149. Schofield AV and Bernard O (2013) Rho-associated coiled-coil kinase (ROCK) sig¬naling and disease. Crit Rev Biochem Mol Biol 48:301-316.
150. Seasholtz TM, Wessel J, Rao F, Rana BK, Khandrika S, Kennedy BP, Lillie EO, Ziegler MG, Smith DW, and Schork NJ, et al. (2006) Rho kinase polymorphism influences blood pressure and systemic vascular resistance in human twins: role of heredity. Hypertension 47:937-947.
151. Sebbagh M, Hamelin J, Bertoglio J, Solary E, and Bréard J (2005) Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. J Exp Med 201:465-471.
152. Sebbagh M, Renvoizé C, Hamelin J, Riché N, Bertoglio J, and Bréard J (2001) Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apo-ptotic membrane blebbing. Nat Cell Biol 3:346-352.
153. Shah DI and Singh M (2006a) Effect of fasudil on macrovascular disorder-induced endothelial dysfunction. Can J Physiol Pharmacol 84:835-845.
154. Shah DI and Singh M (2006b) Involvement of Rho-kinase in experimental vascular endothelial dysfunction. Mol Cell Biochem 283:191-199.
155. Shi J, Zhang YW, Summers LJ, Dorn GW 2nd, and Wei L (2008) Disruption of ROCK1 gene attenuates cardiac dilation and improves contractile function in pathological cardiac hypertrophy. J Mol Cell Cardiol 44:551-560.
156. Shi J, Zhang YW, Yang Y, Zhang L, and Wei L (2010) ROCK1 plays an essential role in the transition from cardiac hypertrophy to failure in mice. J Mol Cell Cardiol 49: 819-828.
157. Shibuya M, Hirai S, Seto M, Satoh S, and Ohtomo E; Fasudil Ischemic Stroke Study Group (2005) Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci 238:31-39.
158. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takemae T, and Hidaka H, et al. (1992) Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo¬controlled double-blind trial. J Neurosurg 76:571-577.
159. Shimizu T, Fukumoto Y, Tanaka S, Satoh K, Ikeda S, and Shimokawa H (2013) Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pul¬monary hypertension in mice. Arterioscler Thromb Vasc Biol 33:2780-2791.
160. Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M, Noda Y, Matsumura F, Taketo MM, and Narumiya S (2005) ROCK-I regulates closure ofthe eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 168: 941-953.
161. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, and Minamino T, et al. (2002) Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 40:751-761.
162. Shin HK, Salomone S, Potts EM, Lee S-W, Millican E, Noma K, Huang PL, Boas DA, Liao JK, and Moskowitz MA, et al. (2007) Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J Cereb Blood Flow Metab 27:998-1009.
163. Sin WC, Chen XQ, Leung T, and Lim L (1998) RhoA-binding kinase alpha trans¬location is facilitated by the collapse of the vimentin intermediate filament net¬work. Mol Cell Biol 18:6325-6339.
164. Smith CJ, Santhanam L, and Alexander LM (2013) Rho-Kinase activity and cuta¬neous vasoconstriction is upregulated in essential hypertensive humans. Microvasc Res 87:58-64.
165. Soga J, Noma K, Hata T, Hidaka T, Fujii Y, Idei N, Fujimura N, Mikami S, Maruhashi T, and Kihara Y, et al.; ROCK Study Group (2011) Rho-associated kinase activity, endothelial function, and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 31:2353-2359.
166. Song Y, Chen X, Wang LY, Gao W, and Zhu MJ (2013) Rho kinase inhibitor fasudil protects against ß-amyloid-induced hippocampal neurodegeneration in rats. CNS Neurosci Ther 19:603-610.
167. Sopko NA, Hannan JL, and Bivalacqua TJ (2014) Understanding and targeting the Rho kinase pathway in erectile dysfunction. Nat Rev Urol 11:622-628.
168. Stirzaker RA, Biswas PS, Gupta S, Song L, Bhagat G, and Pernis AB (2012) Ad¬ministration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/ W F1 female mice. Lupus 21:656-661.
169. Stockton RA, Shenkar R, Awad IA, and Ginsberg MH (2010) Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med 207:881-896.
170. Sung JK, Miao L, Calvert JW, Huang L, Louis Harkey H, and Zhang JH (2003) A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat. Brain Res 959:29-38.
171. Suzuki Y, Shibuya M, Satoh S, Sugimoto Y, and Takakura K (2007) A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemor¬rhage. Surg Neurol 68:126-131; discussion 131-132.
172. Takata M, Tanaka H, Kimura M, Nagahara Y, Tanaka K, Kawasaki K, Seto M, Tsuruma K, Shimazawa M, and Hara H (2013) Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol 170:341-351.
173. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, and Araie M; K-115 Clinical Study Group (2013) Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 156:731-736.
174. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, and Araie M; K-115 Clinical Study Group (2015) Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Oph¬thalmol 93:e254-e260.
175. Thumkeo D, Keel J, Ishizaki T, Hirose M, Nonomura K, Oshima H, Oshima M, Taketo MM, and Narumiya S (2003) Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol 23:5043-5055.
176. Thumkeo D, Shimizu Y, Sakamoto S, Yamada S, and Narumiya S (2005) ROCK-I and ROCK-II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo. Genes Cells 10:825-834.
177. Thumkeo D, Watanabe S, and Narumiya S (2013) Physiological roles ofRho and Rho effectors in mammals. Eur J Cell Biol 92:303-315.
178. Tokushige H, Inatani M, Nemoto S, Sakaki H, Katayama K, Uehata M, and Tanihara H (2007) Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Oph¬thalmol Vis Sci 48:3216-3222.
179. Tonges L, Frank T, Tatenhorst L, Saal KA, Koch JC, Szego EM, Bahr M, Weishaupt JH, and Lingor P (2012) Inhibition of rho kinase enhances survival ofdopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson’s disease. Brain 135:3355-3370.
180. Toque HA and Caldwell RW (2014) New approaches to the design and discovery of therapies to prevent erectile dysfunction. Expert Opin Drug Discov 9: 1447-1469.
181. Torka R, Thuma F, Herzog V, and Kirfel G (2006) ROCK signaling mediates the adoption of different modes of migration and invasion in human mammary epi¬thelial tumor cells. Exp Cell Res 312:3857-3871.
182. Tsounapi P, Saito M, Kitatani K, Dimitriadis F, Ohmasa F, Shimizu S, Kinoshita Y, Takenaka A, and Satoh K (2012) Fasudil improves the endothelial dys¬function in the aorta of spontaneously hypertensive rats. Eur J Pharmacol 691:182-189.
183. Van de Velde S, Van Bergen T, Sijnave D, Hollanders K, Castermans K, Defert O, Leysen D, Vandewalle E, Moons L, and Stalmans I (2014) AMA0076, a novel, lo¬cally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci 55: 1006-1016.
184. van Nieuw Amerongen GP, Beckers CM, Achekar ID, Zeeman S, Musters RJ, and van Hinsbergh VW (2007) Involvement of Rho kinase in endothelial barrier mainte¬nance. Arterioscler Thromb Vasc Biol 27:2332-2339.
185. Vesterinen HM, Currie GL, Carter S, Mee S, Watzlawick R, Egan KJ, Macleod MR, and Sena ES (2013) Systematic review and stratified meta-analysis of the efficacy of RhoA and Rho kinase inhibitors in animal models of ischaemic stroke. Syst Rev 2:33.
186. Vicari RM, Chaitman B, Keefe D, Smith WB, Chrysant SG, Tonkon MJ, Bittar N, Weiss RJ, Morales-Ballejo H, and Thadani U; Fasudil Study Group (2005) Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo¬controlled, phase 2 trial. J Am Coll Cardiol 46:1803-1811.
187. Wang HW, Liu PY, Oyama N, Rikitake Y, Kitamoto S, Gitlin J, Liao JK, and Boisvert WA (2008) Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/-mice. FASEB J 22:3561-3570.
188. Wang J, Liu X, and Zhong Y (2013) Rho/Rho-associated kinase pathway in glaucoma (Review). Int J Oncol 43:1357-1367.
189. Wang Y, Zheng XR, Riddick N, Bryden M, Baur W, Zhang X, and Surks HK (2009) ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. Circ Res 104:531-540.
190. Wang YX, da Cunha V, Martin-McNulty B, Vincelette J, Li W, Choy DF, Halks-Miller M, Mahmoudi M, Schroeder M, and Johns A, et al. (2005) Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. Eur J Pharmacol 512:215-222.
191. Ward Y, Yap SF, Ravichandran V, Matsumura F, Ito M, Spinelli B, and Kelly K (2002) The GTP binding proteins Gem and Rad are negative regulators of the Rho¬Rho kinase pathway. J Cell Biol 157:291-302.
192. Watzlawick R, Sena ES, Dirnagl U, Brommer B, Kopp MA, Macleod MR, Howells DW, and Schwab JM (2014) Effect and reporting bias of RhoA/ROCK-blockade intervention on locomotor recovery after spinal cord injury: a systematic review and meta-analysis. JAMA Neurol 71:91-99.
193. Wei L, Roberts W, Wang L, Yamada M, Zhang S, Zhao Z, Rivkees SA, Schwartz RJ, and Imanaka-Yoshida K (2001) Rho kinases play an obligatory role in vertebrate embryonic organogenesis. Development 128:2953-2962.
194. Wen W, Liu W, Yan J, and Zhang M (2008) Structure basis and unconventional lipid membrane binding properties of the PH-C1 tandem of rho kinases. J Biol Chem 283:26263-26273.
195. Whitehead KJ, Chan AC, Navankasattusas S, Koh W, London NR, Ling J, Mayo AH, Drakos SG, Jones CA, and Zhu W, et al. (2009) The cerebral cavernous malfor¬mation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med 15:177-184.
196. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, Dominiak P, and Liao JK (2004) inhibition of Rho-kinase leads to rapid activation of phospha-tidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arte-rioscler Thromb Vasc Biol 24:1842-1847.
197. Wong CCL, Wong CM, Tung EKK, Man K, and Ng iOL (2009) Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor in¬vasion. Hepatology 49:1583-1594.
198. Wu J, Li J, Hu H, Liu P, Fang Y, and Wu D (2012) Rho-kinase inhibitor, fasudil, prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the ischemic penumbra of rat brain. Cell Mol Neurobiol 32:1187-1197.
199. Yanazume T, Hasegawa K, Wada H, Morimoto T, Abe M, Kawamura T, and Sasayama S (2002) Rho/ROCK pathway contributes to the activation of ex¬tracellular signal-regulated kinase/GATA-4 during myocardial cell hypertrophy. J Biol Chem 277:8618-8625.
200. Yang X, Li Q, Lin X, Ma Y, Yue X, Tao Z, Wang F, Mckeehan WL, Wei L, and Schwartz RJ, et al. (2012) Mechanism of fibrotic cardiomyopathy in mice expressing truncated Rho-associated coiled-coil protein kinase 1. FASEB J26:2105-2116.
201. Yao L, Chandra S, Toque HA, Bhatta A, Rojas M, Caldwell RB, and Caldwell RW (2013) Prevention ofdiabetes-induced arginase activation and vascular dysfunction by Rho kinase (ROCK) knockout. Cardiovasc Res 97:509-519.
202. Yoneda A, Multhaupt HA, and Couchman JR (2005) The Rho kinases i and ii reg¬ulate different aspects of myosin ii activity. J Cell Biol 170:443-453.
203. Yoo SY, Kim J, Cheong S, Shin DH, Jang J, Lee C, Tahk SJ, Shin JH, Choi SY, and Yoon MH (2012) Rho-associated kinase 2 polymorphism in patients with va¬sospastic angina. Korean Circ J 42:406-413.
204. Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, Depoil D, Rao N, Liu B, and Wei J, et al. (2014) Selective oral ROCK2 inhibitor down-regulates iL-21 and iL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA 111:16814-16819.
205. Zee RY, Wang QM, Chasman Di, Ridker PM, and Liao JK (2014) Gene variations of ROCKs and risk of ischaemic stroke: the Women’s Genome Health Study. Clin Sci (Lond) 126:829-835.
206. Zhang YM, Bo J, Taffet GE, Chang J, Shi J, Reddy AK, Michael LH, Schneider MD, Entman ML, and Schwartz RJ, et al. (2006) Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB J 20: 916-925.
207. Zhou L, Liu F, Huang XR, Liu F, Chen H, Chung AC, Shi J, Wei L, Lan HY, and Fu P (2011) Amelioration of albuminuria in ROCK1 knockout mice with streptozotocin-induced diabetic kidney disease. Am J Nephrol 34:468-475.
208. Zhou Q and Liao JK (2009) Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des 15:3108-3115.
209. Zhou Q, Mei Y, Shoji T, Han X, Kaminski K, Oh GT, Ongusaha PP, Zhang K, Schmitt H, and Moser M, et al. (2012) Rho-associated coiled-coil-containing kinase 2 de¬ficiency in bone marrow-derived cells leads to increased cholesterol efflux and decreased atherosclerosis. Circulation 126:2236-2247.
210. Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, Gonzalez-DeWhitt PA, Gelfanova V, Hale JE, and May PC, et al. (2003) Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302:1215-1217.
211. Zhu M, Liu PY, Kasahara Di, Williams AS, Verbout NG, Halayko AJ, Fedulov A, Shoji T, Williams ES, and Noma K, et al. (2011) Role of Rho kinase isoforms in murine allergic airway responses. Eur Respir J 38:841-850.